KURA News & Events

Kura Oncology highlighted new clinical and translational data supporting darlifarnib as a potential foundational combination platform for KRAS-mutant cancers and other targeted therapy settings. The data, presented at the 2026 American Society of Clinical Oncology Annual Meeting, support Kura's strategy to expand its next-generation farnesyl transferase inhibitor, or FTI, through a new platform study designed to efficiently evaluate multiple combinations and identify opportunities to improve the depth and durability of responses to targeted therapies. In preclinical models, translational data demonstrated that darlifarnib inhibits RHEB farnesylation and sustains suppression of mTORC1 signaling, a pathway implicated in adaptive resistance to KRAS inhibition. Preclinical studies further showed enhanced anti-tumor activity across multiple classes of RAS inhibitors, including mutant-selective and multi-selective RAS inhibitors, as well as pan-KRAS and pan-RAS approaches, and demonstrated tumor regressions in models previously exposed to KRAS inhibitor therapy. In the ongoing FIT-001 study, darlifarnib plus adagrasib demonstrated promising anti-tumor activity in heavily pretreated patients with KRAS G12C-mutated pancreatic ductal adenocarcinoma, non-small cell lung, and colorectal cancers. Among 26 response-evaluable patients, tumor shrinkage was observed in 77% of patients overall and in 94% of KRAS inhibitor-naive patients. Confirmed objective response rates included 67% in PDAC, 50% in NSCLC, and 29% in KRAS inhibitor-naive CRC. The ASCO findings represent the third clinical validation of Kura's FTI combination strategy, following previously reported activity in renal cell carcinoma and PIK3CA-mutated head and neck cancer. Kura believes the opportunity for darlifarnib extends beyond KRAS G12C. The Company plans to initiate a platform study designed to evaluate darlifarnib across multiple targeted therapy combinations and disease settings. The first planned combination in the new study will be darlifarnib plus daraxonrasib in 2L+ KRAS-mutant PDAC, which is expected to enter Phase 1a evaluation in early 2027.

Kura Oncology reported compelling first-in-human data from the FIT-001 clinical trial of its next-generation farnesyl transferase inhibitor, or FTI, darlifarnib in combination with adagrasib in heavily pretreated patients with KRAS G12C-mutated advanced solid tumors. The results will be presented at the 2026 American Society of Clinical Oncology, or ASCO, Annual Meeting on May 30. The combination of darlifarnib plus adagrasib demonstrated meaningful antitumor activity in heavily pretreated pancreatic ductal adenocarcinoma, or PDAC, and non-small cell lung cancer, or NSCLC, patients with prior KRAS inhibitor, or KRASi, exposure, as well as KRASi-naive colorectal cancer, or CRC, patients. These data provide clinical proof-of-mechanism for Kura's FTI platform as a precision combination that blocks RHEB-dependent mTORC1 signaling, a key resistance pathway shared across multiple targeted therapy classes. Key Highlights in Phase 1a, N=30; 26 response evaluable, are: 77% of response-evaluable patients achieved tumor shrinkage, including 94% of response-evaluable, KRASi-naive patients; Objective response rate, or ORR,: 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naive CRC; Responses were observed across dose levels and tumor types; Clinical activity observed in heavily pre-treated patients, including those with prior KRASi exposure In NSCLC, confirmed partial response and 84% target lesion reduction observed in a patient previously treated with a KRAS inhibitor; Median follow-up time: PDAC 6.7 months; NSCLC 6.9 months; CRC 8.9 months; 37% of patients remained on study treatment at time of data cutoff.; Combination was well tolerated with a manageable safety profile; Best Percent Change in Target Lesion Size: PDAC, NSCLC and CRC; Best Percent Change in Target Lesion Size: PDAC, NSCLC and CRC. The waterfall plot shows best percent change from baseline in target lesion size among response-evaluable patients. Objective responses were observed across all three tumor types and dose levels. Bars that extend below the -30% horizontal line indicate target lesion reductions meeting the RECIST threshold for response, and all PRs represent confirmed partial responses.

High-flying semiconductors and memory names were some of the worst-hit stocks on Tuesday as investors - fretting over the speed of the AI and data center demand frenzy - pulled back on Tech exposure.  The worst performer in the S&P 500 - Qualcomm- was down over 11% after the stock's advance of 87% in just 3 weeks at its highs overnight.  Intel, Sandisk, Western Digitaland Micron,were down 7%, 6%, 5%, and 4% respectively, though all four names remain in the top 10 ranking in terms of S&P 500's best performers for the year.  The rotation from high-momentum to value benefited the Healthcare space, which was the best performing sector in the benchmark today but remains the index's worst sector for the year - Humanawas a standout here with a gain of over 7%, as the stock has now nearly doubled from its late-March lows.Sentiment is cautious in the evening session as S&P e-minis and Nasdaq 100 contracts are both flat.  In commodities, WTI Crude Oil remains bid just below $102 per barrel as Middle East tension remains unresolved while base metals continue to trend higher as traders adjust to re-heating inflation expectations, with Copper up for the 4th straight session above $6.60.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Velo3Dup 22.3%SELLAS Life Sciences Groupup 14.4%Nextpowerup 10.5%Arterisup 7.0%ALSO HIGHER -Energy Vaultup 5.1% after announcing strategic development agreement with EskomDOWN AFTER EARNINGS -Karman Holdingsdown 10.4%Resideo Technologiesdown 7.3%Infinity Natural Resourcesdown 7.2%Astronicsdown 5.4%Paysigndown 3.8%Kura Oncologydown 2.1%Oklodown 1.5%

Reports Q1 revenue $18.27M, consensus $25.92M. As of March 31, Kura had $580.8M in cash, cash equivalents and short-term investments, compared to $667.2M as of December 31, 2025. The company believes its cash, cash equivalents and short-term investments as of March 31, when combined with $180M in anticipated payments under the collaboration agreement with Kyowa Kirin, will be sufficient to fund the ziftomenib AML program through the topline results from the first pivotal Phase 3 KOMET-017 frontline trial, anticipated in 2028.